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Endothelial cellThe scavenger receptor FEEL-1/stabilin-1 is known as the marker of alternatively activated macrophage and
sinusoidal endothelial cell. FEEL-1/stabilin-1 is a multifunctional transmembrane glycoprotein that is
implicated in bacterial infection, diabetes, atherosclerosis, wound healing, and innate immunity. In the
current study, we have identiﬁed the phox-homology domain containing protein SNX17 as a novel
interaction partner of FEEL-1/stabilin-1 in endothelial cells. SNX17 directly interacts with FEEL-1/stabilin-1
and regulates its trafﬁcking. Studies using the cytoplasmic domain of truncated or mutant FEEL-1/stabilin-1
suggest that the NPxF motif of the FEEL-1/stabilin-1 cytoplasmic tail is required for its interaction with
SNX17. By transfecting cells with small interfering RNA targeting SNX17, total cellular FEEL-1/stabilin-1
expression and FEEL-1/stabilin-1-mediated ligand uptake were signiﬁcantly decreased due to the
enhancement of FEEL-1/stabilin-1 protein degradation. Our results identify SNX17 as a novel interaction
partner of FEEL-1/stabilin-1 in endothelial cells.tor protein-2; APC, antigen-
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FEEL-1 and FEEL-2,whichare also knownas stabilin-1 and stabilin-2,
respectively, are a novel family (type H) of scavenger receptors that are
expressed in endothelial cells [1,2]. Stabilin-1 was initially identiﬁed as
anMS-1 antigen expressed in sinusoidal endothelial cells in the human
spleen [3,4] whereas stabilin-2 was detected as a hyaluronan-binding
protein [5–7]. They are type I transmembrane proteins that contain a
short cytoplasmic tail (CT), a transmembrane region, and a large
extracellular region containing seven fasciclin domains, multiple
epidermal growth factor-like domains, and a single C-type lectin-like
hyaluronan-binding linkdomain [1,8]. Both FEEL-1/stabilin-1 and FEEL-
2/stabilin-2 have predominant localization in EEA-1 (early endosomal
antigen1) positive endosomes, andbothproteins canbedetectedon thesurface of cells. There is no clear difference on the amount of FEEL-1/
stabilin-1 and FEEL-2/stabilin-2 on the cell surface. [9–11].
FEEL-1/stabilin-1 is a multiligand endocytic receptor that recog-
nizes various negatively charged macromolecules such as Gram-
positive and Gram-negative bacteria; modiﬁed low-density lipopro-
teins (LDLs), i.e., acetylated LDL (Ac-LDL) and oxidized-LDL (Ox-LDL)
[1]; advanced glycation end products (AGE) [12]; secreted protein
acidic and rich in cysteine (SPARC) [13]; heat shock protein 70 (Hsp
70) [14]; and placental lactogen (PL) [15]. These ligands are
implicated in bacterial infection, diabetes, atherosclerosis, wound
healing, innate immunity, fetal growth, and placental angiogenesis,
suggesting the pathophysiological signiﬁcance of FEEL-1/stabilin-1
[2].
It has been reported that the CT of FEEL-1/stabilin-1 plays roles in
two steps of its intracellular trafﬁcking: (1) receptor-mediated
endocytosis and recycling and (2) shuttling between the endosomal
compartment and the trans-Golgi network (TGN) [16]. The above
mentioned intracellular trafﬁcking is mediated by Golgi-localized, γ-
ear-containing 5′-diphosphate-ribosylation factor-binding adaptors
(GGA), which interact with the DDSLL motif of the CT in alternatively
activated human macrophages [9,11]. FEEL-1/stabilin-1 has also
shown to associate with clathrin and adaptor protein-2 (AP-2) in
rat liver sinusoidal endothelial cells [9]. Nevertheless, themechanisms
involved in FEEL-1/stabilin-1 endocytosis and recycling are still
unknown.
The sorting nexins (SNXs) are a family of proteins involved in
intracellular membrane trafﬁcking that are characterized by the
presence of a phox-homology (PX) domain, which is thought to play a
Fig. 1. Receptor activities of the cytoplasmic tail deletionmutant of FEEL-1/stabilin-1. (A)A schematicdrawingof the cytoplasmic tail of FEEL-1/stabilin-1. Residuenumber1 is thearginine
residue2500 following the putative transmembrane domain [1]. Deleted constructs and thepositions of theNPVF andDDSLL domains are depicted. (B) The receptor activity of cytoplasmic
tail mutants of FEEL-1/stabilin-1 transiently expressed in 293A cells. 0.6 μg of plasmid was transfected with Lipofectamine 2000 (Invitrogen) into 1×105 of 293A cells in a 24-well plate.
After 48 h of transfection, the cells were incubated with 1 μg/ml of DiI Ac-LDL for 1 h at 37 °C. After washing, the cells were solubilized, and the cellular association of DiI Ac-LDL was
determined ﬂuorescently [1]. Data are expressed asmean±SD. (C)Western blot analysis of truncated FEEL-1/stabilin-1. 293A cell lysate that expressed truncated FEEL-1/stabilin-1 was
analyzed using monoclonal antibody to FEEL-1/stabilin-1 that recognizes its extracellular domain [1]. (D) Confocal microscopy of 293A cells transiently expressing wild-type or
cytoplasmic tail mutant of FEEL-1/stabilin-1. 293A cellswere seeded into 24-well plate and transfectedwith cDNA forwild-type or cytoplasmic tail mutants of FEEL-1/stabilin-1. The next
day after transfection, cells were trypsinized and seeded into wells containing sterilized coverslips. After 48 h of transfection, cells were incubated with 1 μg/ml of DiI Ac-LDL for 1 h and
then ﬁxed in 3% (w/v) paraformaldehyde for 10 min. The expression of FEEL-1/stabilin-1was detected bymonoclonal antibody that recognizes its extracellular domain, using TSA Biotin
System (NEN Life Science Products, MA, USA) and streptavidin conjugate Alexa Fluor 488 (Invitrogen).
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Fig. 2. Interaction of SNX17with FEEL-1/stabilin-1. (A) Schematic drawing of SNX17 and cDNA interacting with the FEEL-1/stabilin-1 cytoplasmic tail. PX and FERM are depicted as phox-
homology (PX) domain and a protein 4.1, ezrin, radixin, andmoesin (FERM) domain. The arrows depict cDNAs interacting with the FEEL-1/stabilin-1 cytoplasmic tail obtained after yeast
two-hybrid screening. (B) Interaction of SNX17with FEEL-1/stabilin-1. 293A cell lysate that expressed both SNX17 and FEEL-1/stabilin-1 was immunoprecipitated with SNX17 antibody,
and western blot was detected using anti FEEL-1/stabilin-1 (lane 1, lysate; lane 2, immunoprecipitated without antibody; lane 3, 0.2 μg of anti SNX17; lane 4, 0.4 μg of anti SNX17). (C)
Schematic representationof 9×myc-SNX17andtruncatedconstructs andmyc-SNX17pull-downassayby FEEL-1/stabilin-1cytoplasmic tail. GSTorGSTFEEL-1/stabilin-1 tail fusion (GST1–
71)orwith amutation in theSNX17-bindingmotif (GST 1–7143A)were immobilizedonglutathione-agarose beads and incubatedwith293A cell lysate ofmyc-SNX17 truncated constructs.
Bound proteins were analyzed by western blot using anti-myc antibody.
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speciﬁc phospholipids [17]. SNX17 is a member of the SNX family that
possesses a PX domain followed by a protein 4.1, ezrin, radixin, and
moesin (FERM) domain [18]. The FERM domain and C-terminal region
of the proteins are considered to be involved in the binding of their
partners. Like many SNXs, SNX17 is localized in early endosomal
vacuoles and recycling tubules and has been shown to interact with
several proteins, such as LDL receptor, LDL receptor-related protein
(LRP), P-selectin and amyloid precursor protein and modulate their
endocytosis and recycling processes [19–21].
To elucidate the mechanism underlying the intracellular trafﬁcking
of FEEL-1/stabilin-1,we sought toﬁndthe FEEL-1/stabilin-1-interacting
molecule that participates in receptor trafﬁcking. In this study, we
demonstrate for the ﬁrst time that SNX17 binds to the CT of FEEL-1/stabilin-1. Our results suggest that SNX17 interacts with FEEL-1/
stabilin-1 and thus modiﬁes its intracellular recycling and degradation
in endothelial cells.
2. Materials and methods
2.1. Plasmid constructs
For the expression of CT-deleted mutants in 293A cells, stop codons
were introduced into theCTby thepolymerase chain reaction (PCR)using
plasmid DNA (pcDNA3-FEEL-1/stabilin-1) as a template [1]. pLexA
(Clontech, Mountain View, CA, USA) was used for the expression of bait
proteins in yeast. The cDNA of the whole CT (amino acids 2473–2570 of
human FEEL-1/stabilin-1) containing the transmembrane portion of the
Fig. 3. The importance of the NPVF motif-containing sequence of FEEL-1/stabilin-1 in the interaction with SNX17. (A) A schematic drawing of truncated FEEL-1/stabilin-1
cytoplasmic tail mutants fused to glutathione-S-transferase (GST). Residue number 1 is the arginine residue 2500 following the putative transmembrane domain [1]. (B) Analysis of a
pull-down assay by western blotting. Lysate containing SNX17 transiently expressed in 293A cells was incubated with cytoplasmic tail mutants fused to GST, which were bound to
glutathione-Sepharose. After washing the beads, the bound proteins were separated by SDS-PAGE. Lane indicates the cytoplasmic tail mutants fused to GST or intact GST. After
transferring the proteins to PVDF membrane, SNX17 was detected using anti-SNX17 antibody. (C) The gels were also stained with Coomassie Brilliant Blue R-250 as loading control.
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NotI fragment into thepLexAEcoRI andNotI sitesdownstreamof theLexA
sequence to produce pLexA-FEEL-1/CT. For mammalian expression, full-
length SNX17 cDNAwas obtained fromOpen Biosystems (Huntsville, AL,
USA). For plasmids encoding GST fused to the cytoplasmic domain of
FEEL-1/stabilin-1, appropriate fragments were ampliﬁed by PCR and
cloned into pGEX-4T1 (GE Healthcare UK, Chalfont, St. Giles, UK). The
point mutations were introduced into the CT of FEEL-1/stabilin-1 by
inverse PCR using a KOD -Plus- Mutagenesis Kit (Toyobo, Osaka, Japan).
9×myc-tagged SNX17 was constructed by PCR using pTN184 (pBS-myc
in XbaI(KS)) (National Bio Resource Project, NBRP, Japan) and full-length
SNX17. 9×myc-tagged SNX17 domain constructs were constructed by
inverse PCR using a KOD -Plus- Mutagenesis Kit (Toyobo, Osaka, Japan).
All constructs were veriﬁed by nucleotide sequencing.
2.2. Yeast two-hybrid screening
Saccharomyces cerevisiae EGY48[p8oplacZ] was grown and used as
the host for yeast two-hybrid screening as described by the supplier
(Yeast Protocols Handbook, Clontech) The human umbilical vein
endothelial cell (HUVEC) cDNA library was constructed in a pB42AD
vector. After the simultaneous introduction of pLexA-FEEL-1/CT and
the HUVEC cDNA library into S. cerevisiae EGY48[p8oplacZ], 2.4×106
cotransformants were selected and ampliﬁed on SD/-His/-Trp/-Ura
plates. Cotransformants (1.0×107) were selected on inductionmedium containing 5-bromo-4-chloro-3-indolyl-β-D-galactoside (X-
gal) to screen for the expression of lacZ and LEU2 reporter genes. The
cDNA from selected clones was ampliﬁed by PCR and characterized
further by nucleotide sequencing.
2.3. Physical interaction of SNX17 with the cytoplasmic domain of the
FEEL-1/stabilin-1
GST-CT fusion proteins were bound to glutathione S-Sepharose
beads according to the supplier's instructions (Bulk GST Puriﬁcation
Module, GE Healthcare UK). SNX17 protein was produced in 293A cells
(Invitrogen, Carlsbad, CA, USA) from a pCMV SPORT6 construct of
human SNX17. The 293A cell lysate was prepared using Tris-buffered
saline containing 0.25% (v/v) NP-40 (buffer A) and protease inhibitors
(Complete Protease Inhibitor Cocktail Tablets, Roche Diagnostics,
Mannheim,Germany). Then, the293Acell lysate (200 μl)was incubated
with GST-fusion protein bound to glutathione-Sepharose beads (ap-
proximately 40 μl of a 50% slurry of beads) in buffer A at 4 °C for 3 h on a
rotating wheel. The beads were washed three times with the same
buffer, resuspended in 30 µl of sodium dodecyl sulphate (SDS) gel
sample buffer containing 40 mMdithiothreitol (DTT), and aliquotswere
loaded onto gels of 8% SDS-polyacrylamide gels for electrophoresis. The
gels were analyzed by western blot analysis using anti SNX17
antibodies. The gels were also stained with Coomassie Brilliant Blue R-
250 as loading control.
Fig. 4. The NPxF motif of the FEEL-1/stabilin-1 cytoplasmic tail is responsible for its
interaction with SNX17. (A) A schematic drawing of FEEL-1/stabilin-1 cytoplasmic tail
mutants. Residue number 1 is the arginine residue 2500 following the putative
transmembrane domain [1]. (B) Analysis of a pull-down assay by western blotting. Lysate
containing SNX17 transiently expressed in 293A cells was incubated with a cytoplasmic
tail mutant fused to glutathione-S-transferase (GST), which was bound to glutathione-
Sepharose. SNX17 was detected as described inMaterials and methods. (C) The gels were
also stained with Coomassie Brilliant Blue R-250 as loading control.
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HUVECs were solubilized with buffer A and protease inhibitors, and
soluble cell lysate were immunoprecipitated with anti SNX17 antibody.
Thebeadswerewashed three timeswith the samebuffer, resuspended in
30 µl of SDS gel sample buffer containing 40 mMDTT, and aliquots were
loaded onto gels of 6% SDS-polyacrylamide gels for electrophoresis. The
gelswere analyzed bywestern blot analysis using anti FEEL-1 antibodies.
The different 9×myc-tagged SNX17 domain constructs were
expressed in 293A cells and solubilized with buffer A and protease
inhibitors. Then the lysatewere incubatedwithglutathione-agarosebeads
that had bound with GST alone or GST-FEEL-1/stabilin-1 cytoplasmic
domain without (GST 1–71) or with a mutation in the SNX17 binding
motif (GST 1–71 43A). The beadswerewashed three timeswith the same
buffer, resuspended in 30 µl of SDS gel sample buffer containing 40 mM
DTT, and aliquotswere loadedonto gels of 8% SDS-polyacrylamide gels for
electrophoresis. The gels were analyzed by western blot analysis using
anti-myc antibody (Nacali Tesque, Kyoto, Japan).
2.4. Detection of SNX17
A commercial rabbit antiserum (Proteintech Group, Inc. Chicago,
IL, USA) or goat antiserum (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA, USA) was used to detect the SNX17 protein. Anti-FEEL-1 antisera,
which recognizes the CT of FEEL-1/stabilin-1, was used for immuno-
logical detection as described previously [1]. For the detection of cell
surface truncated mutants of FEEL-1/stabilin-1 on 293A cells or FEEL-
1/stabilin-1 on HUVECs, monoclonal antibody to FEEL-1/stabilin-1
were used [1].
2.5. Small interfering RNA (siRNA) transfection
siRNA was synthesized as Stealth™ RNAi (Invitrogen) and Stealth™
RNAi Negative Control Medium GC Duplex was purchased fromInvitrogen. The nucleotide sequences were AACUGUUGAAAGUCUCG-
CUGCUCC (siRNA SNX17(I)) or UUGAGAGUUUGACCAUAGACUCCCG
(siRNA SNX17(II)) for SNX17 and AUGAGACAGCUGUUAAUUUCCUGGC
(siRNA FEEL-1(I)) orAUCCUCCAUUGUUCUUAGAGCAGGG (siRNAFEEL-
1(II)) for FEEL-1/stabilin-1. The 293A cells (1×105 cells/24-well plate)
were cotransfected with pcDNA3/FEEL-1 and siRNA for SNX17 or
control siRNA using Lipofectamine 2000 (Invitrogen) as recommended
by the supplier. After the transfected cells hadbeen cultured for a further
48 h, theywere analyzed as follows: Thecellswere incubatedwith1 µg/
ml of DiI Ac-LDL for 1 h and solubilizedwith 1% Triton X-100 containing
protease inhibitors (Complete Protease Inhibitor Cocktail Tablets, Roche
Diagnostics). Then, the ﬂuorescence intensity of the lysate was
measured using a ﬂuorescence multiple plate reader (CytoFluorII,
PerSeptive Biosystems) [1].
2.6. Biotinylated FEEL-1 degradation
293A cells were cotransfected with pcDNA3/FEEL-1 and siRNA for
SNX17 or control siRNA as described above. The cells were washed
with cold phosphate-buffered saline (PBS), and cell surface proteins
were labeled with EZ-Link Sulfo-NHS-SS-Biotin (1 mg/ml) (Pierce,
Rockford, IL, USA) in cold PBS at 4 °C for 30 min. The reaction was
terminated by washing and incubating the cells in PBS containing
100 mM glycine at 4 °C for 10 min. The cells were then incubated at
37 °C in Dulbecco's modiﬁed Eagle's medium (DMEM) containing 10%
FCS for the indicated periods. After solubilization of the cells with
buffer A, which contained protease inhibitors, biotinylated proteins
were precipitated from the lysate by using streptavidin-agarose
(Sigma, Saint Louis, MO, USA) before being analyzed by western
blotting. HiMark Pre-stained HMW Standard (Invitrogen) was run
simultaneously to estimate the molecular weight of the protein on
blots.
2.7. Cell surface expression assay—gene silencing by siRNA
HUVECs were transfected with RNAiMAX and stealth RNAi for
24 h. After transfection, the medium was changed, and the cells were
cultured further for 24 h and analyzed as follows: The cells were
incubated with 1 μg/ml of DiI (1:1′-dioctadecyl-3:3:3′:3′-tetra-
methyl-indocarbo-cyanine perchlorate) Ac-LDL for 3 h at 37 °C.
After solubilization of the cells with 1% Triton X-100 containing
protease inhibitors (Complete Protease Inhibitor Cocktail Tablets,
Roche Diagnostics) the ﬂuorescence intensity of the lysate was
measured using a ﬂuorescence multiple plate reader (CytoFluorII,
PerSeptive Biosystems, Framingham, MA, USA) [1]. HUVECs were
biotinylated with EZ-Link Sulfo-NHS-SS-Biotin (1 mg/ml) (Pierce,
Rockford, IL, USA) in cold PBS at 4 °C for 30 min. The reaction was
terminated by washing and incubating the cells in PBS containing
100 mM glycine at 4 °C for 10 min. After solubilization of the cells
with buffer A, which contained protease inhibitors, biotinylated
proteins were precipitated from the lysate by using streptavidin-
agarose (Sigma, Saint Louis, MO, USA) before being analyzed by
western blotting.
2.8. Confocal microscopy of cell surface expression of FEEL-1/stabilin-1
293Acellswere seeded into24-well plate and transfectedwith cDNA
for wild-type or cytoplasmic tail mutants of FEEL-1/stabilin-1. The next
day after transfection, cells were trypsinized and seeded into wells
containing sterilized coverslips. After 48 h of transfection, cells were
incubatedwith 1 μg/ml of DiI Ac-LDL for 1 h and then ﬁxed in 3% (w/v)
paraformaldehyde for 10 min. 293A cell clone that expresses wild-type
or F2519Amutant of FEEL-1/stabilin-1was seeded intowells containing
sterilized coverslips. After 48 h of seeding, cells were incubated with
1 μg/ml of DiI Ac-LDL for 1 h and then ﬁxed in 3% (w/v) paraformal-
dehyde for 10 min.HUVECswere seeded intowells containing sterilized
Fig. 5. Receptor activity and cellular distribution of wild-type and F2519A FEEL-1/stabilin-1. (A) The receptor activity of wild-type and F2519A FEEL-1/stabilin-1 transiently expressed in
293A cells. After 48 h of transfection, the cellswere incubatedwith 1 μg/ml ofDiI Ac-LDL for 2 h at 37 °C. Afterwashing the cells, theywere solubilized, and cellular associationwith DiI Ac-
LDLwas determinedﬂuorescently [1]. Data are expressed asmean±SD. (B)Quantiﬁcation of cell surface expression and total cellular expressionofwild-type and F2519A FEEL-1/stabilin-
1 transiently expressed in293Acells. After 48 h of transfection, cell surface proteinswere labeledwith biotin. The cellswere then solubilized and then incubatedwith streptavidin-agarose.
The bound biotinylated FEEL-1/stabilin-1 was detected by western blot analysis. Blots for the 120-kDa form were exposed for longer time. (C) The receptor activity of 293A clones that
expressedwild-type orF2519AFEEL-1/stabilin-1. The cellswere incubatedwith1 μg/ml ofDiI Ac-LDL for 2 h at37 °C. Afterwashing thecells, theywere solubilized, and cellular association
with DiI Ac-LDL was determined ﬂuorescently [1]. (D) Quantiﬁcation of total cellular expression of 293A clones that expressed wild-type or F2519A FEEL-1/stabilin-1.
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transfection, cells were incubated with 1 μg/ml of DiI Ac-LDL for 3 h
and then ﬁxed in 3% (w/v) paraformaldehyde for 10 min. The
expression of FEEL-1/stabilin-1 was detected by monoclonal antibody
that recognizes its extracellular domain, using TSA Biotin System (NEN
Life Science Products, MA, USA) and streptavidin conjugate Alexa Fluor
488 (Invitrogen). Confocal images were obtained using OLMPUS FV
1000-D confocal microscopy.3. Results
3.1. Screening a HUVEC cDNA library by the yeast two-hybrid method for
proteins interacting with the CT of FEEL-1/stabilin-1
To identify the cytoplasmic amino acid sequence of FEEL-1/
stabilin-1 essential to its receptor activity, several cDNAs were
prepared as deletion mutants and expressed in 293A cells. As
Fig. 6. Confocal microscopy of 293A cell clone that expresses wild-type or F2519Amutant of FEEL-1/stabilin-1. 293A cell clone that expresses wild-type or F2519Amutant of FEEL-1/
stabilin-1 was seeded into wells containing sterilized coverslips. After 48 h of seeding, cells were incubated with 1 μg/ml of DiI Ac-LDL for 1 h and then ﬁxed in 3% (w/v)
paraformaldehyde for 10 min. The expression of FEEL-1/stabilin-1 was detected by monoclonal antibody that recognizes its extracellular domain, using TSA Biotin System (NEN Life
Science Products, MA, USA) and streptavidin conjugate Alexa Fluor 488 (Invitrogen).
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as measured by their cellular associationwith DiI Ac-LDL. As expected,
transfection with full-length FEEL-1/stabilin-1 caused a signiﬁcant
increase in this activity. The cells transfectedwith a deletionmutant of
the C-terminal 25 amino acids (Δ25) containing the DDSLL motif of
the GGA adaptor protein binding site [10] showed increased activity,
presumably due to increased steady-state expression (Fig. 1C).
Further deletion of 10 (Δ35) or 44 (Δ69) amino acids from the CT
signiﬁcantly reduced receptor activity, suggesting that the sequence
between 2535 and 2545 was important for such activity. Confocal
microscopy of wild-type or cytoplasmic tail deletion mutants of FEEL-
1/stabilin-1 showed that cells positive for FEEL-1/stabilin-1 were also
positive for the intracellular DiI Ac-LDL containing endosomes
(Fig. 1D).
Then, we searched for proteins that interacted with the amino acid
sequence between 2535 and 2545 by two-hybrid yeast screening
using the full-length cytoplasmic domain as bait. When 1.8×106
clones of a HUVEC cDNA library were screened with the bait, 8 clones
showed reproducible interaction. Of these, four clones encoded a
known protein, named sorting nexin-17 [18]. Fig. 2A shows the
sequence of the SNX17 clones obtained by two-hybrid screening.
Whereas all the sequences contained the entire FERM domain, two
clones lacked the PX domain, suggesting that the PX domain was
dispensable for the interaction between FEEL-1/stabilin-1 and SNX17.
Then we examined whether SNX17 binds to FEEL-1/stabilin-1 in
intact cells. 293A cells transfected with cDNA for FEEL-1/stabilin-1
were solubilized and soluble cell lysate was immunoprecipitated withanti SNX17 antibody. As shown in Fig. 2B, FEEL-1/stabilin-1 and
SNX17 were co-immunoprecipitated with anti SNX17 antibody in a
dose dependent manner. On the other hand, the receptor was barely
detectable in a control precipitate when co-immunoprecipitation was
performed in the absence of antibody, suggesting that the interaction
indeed occurs in intact cells. Fig. 2C depicts the different 9×myc-
tagged SNX17 domain constructs that were expressed in 293A cells.
Cells extracts from transiently transfected 293A cells were incubated
with GST alone or GST-FEEL-1/stabilin-1 cytoplasmic domain without
(GST 1–71) or with a mutation in the SNX17 binding motif (GST 1–71
43A). The western blot in Fig. 2C shows that full-length SNX17 (SNX
1–470) interacted as expected, with the full-length FEEL-1/stabilin-1
cytoplasmic domain but weakly with F2519A mutant or GST alone.
Both the N-terminal half (SNX 1–250) and C-terminal half of SNX17
(SNX 250–470) failed to interact with the FEEL-1/stabilin-1 cytoplas-
mic domain. Truncation of the N-terminal 105 (SNX 105–470) amino
acid residues of SNX17 did not affect FEEL-1/stabilin-1 cytoplasmic
domain binding. However, further truncation within FERM domain of
SNX17 up to 150 amino acids (SNX 150–470) or 200 amino acids (SNX
200–470) resulted in a loss of FEEL-1/stabilin-1 cytoplasmic domain
binding. These results suggested that the C-terminal region, but not
PX domain of SNX17 contribute to FEEL-1/stabilin-1 cytoplasmic
domain binding.
Direct physical interaction between SNX17 and the FEEL-1/stabilin-
1 cytoplasmic domain was then conﬁrmed by a pull-down assay using
various FEEL-1/stabilin-1 CTs fused to glutathione-S-transferase (GST)
that immobilized on glutathione S-Sepharose beads, and the lysate
Fig. 7. Effects of siRNA treatment for SNX17 in 293A cells. (A) The receptor activity for DiI Ac-LDL in 293A cells that had been transfected with siRNAs for SNX17. 293A cells were
cotransfected with FEEL-1/stabilin-1 and siRNA for SNX17 or negative control siRNA. After 48 h of transfection, the cellular association with DiI Ac-LDL was determined [1]. Data are
expressed as mean±SD. (B) Western blot analysis of FEEL-1/stabilin-1 and SNX17 expressed in 293A cells after siRNA transfection. (C) Degradation of FEEL-1/stabilin-1 in 293A
cells treated with negative siRNA or SNX17 siRNA. 293A cells were cotransfected with FEEL-1/stabilin-1 and siRNA for SNX17 or negative control siRNA. After 48 h of transfection,
cell surface proteins were labeled with biotin. The cells were then solubilized after the indicated period and then incubated with streptavidin-agarose. The bound biotinylated FEEL-
1/stabilin-1 was detected by western blot analysis. Total FEEL-1/stabilin-1 was also shown by western blot analysis. 120 kDa form of total FEEL-1/stabilin-1 was shown in separate
panel owing its low content in the total lysate.
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Fig. 3, SNX17 bound to the GST-FEEL-1/CT 1–71 (full-length C-terminal
cytoplasmic domain) and GST-FEEL-1/CT 1–46 mutants but not to the
further deleted mutants GST-FEEL-1/CT 1–36, GST-FEEL-1/CT 1–3 or
GST alone. Furthermore, SNX17 bound to GST-FEEL-1/CT 37–71 but not
to GST-FEEL-1/CT 47–71. Taken together, these results suggest that
FEEL-1/CT 37–47, which contains NPVF motif, was important for the
interaction between FEEL-1/stabilin-1 and SNX17.
3.2. The NPVF motif in FEEL-1/stabilin-1 is required for its interaction
with SNX17
To conﬁrm the role of the NPVF motif in the interaction of FEEL-1/
stabilin-1 with SNX17, we next replaced each residue around the motif
with alanine, and the resultingGST-fusionproteinswere incubatedwiththe 293A cell lysate containing transiently expressed SNX17. As shown
in Fig. 4, single point mutation of N 39, P 40, or F 42 to A resulted in a
complete loss of the interactionwith SNX17, indicating that these amino
acid residues in the NPxF motif of the FEEL-1/stabilin-1 CT were
essential for the interaction between SNX17 and the cytoplasmic
domain of FEEL-1/stabilin-1.
3.3. SNX17 binding to FEEL-1/stabilin-1 is important for the cell surface
expression and stability of FEEL-1/stabilin-1
To elucidate the signiﬁcance of the interaction between FEEL-1/
stabilin-1 and SNX17,wild-type and the F2519A (phenylalanine 2519 to
alanine) mutant of FEEL-1/stabilin-1 were expressed in 293A cells, and
the association of DiI Ac-LDL with these cells was compared (Fig. 5A).
Expression of wild-type FEEL-1/stabilin-1 caused a signiﬁcant increase
Fig. 8. Effects of siRNA treatment for SNX17 in HUVECs. (A) Interaction of SNX17 with
FEEL-1/stabilin-1. HUVECs lysate were immunoprecipitated with SNX17 antibody, and
western blot was detected using anti FEEL-1/stabilin-1 (lane 1, lysate; lane 2,
immunoprecipitated without antibody; lane 3, 0.2 μg of anti SNX17; lane 4, 0.4 μg of
anti SNX17). (B) The receptor activity for DiI Ac-LDL in HUVECs that had been
transfected with siRNA for FEEL-1/stabilin-1 or SNX17 using RNAiMAX (Invitrogen).
After 48 h of transfection, the cellular association of DiI Ac-LDL was determined
ﬂuorescently. Data are expressed as mean±SD. (C) Western blot analysis of FEEL-1/
stabilin-1 and SNX17 expressed in HUVECs after a 48 h siRNA transfection. Cell surface
biotinylated FEEL-1/stabilin-1 was also analyzed by western blot.
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1/stabilin-1 CT mutant F2519A was expressed, the increase in the
association was only marginal. To compare the expression of wild-type
and mutant FEEL-1/stabilin-1 on the cell surface, biotinylation of cell
surface proteins was performed. After solubilization, the biotinylated
receptor was detected by western blot analysis (Fig. 5B). In agreement
with Goerdt et al. [3], three forms (300, 280, and 120-kDa) of the wild-
type receptor were detected on the cells. In contrast, only the 280-kDa
form was detected when the mutant was expressed. These results
suggested that the 280-kDa form of both wild and mutant FEEL-1/
stabilin-1 were expressed on the cell surface independently from the
interaction with SNX17 through the constitutive secretory vesicle. Onthe other hand, cell surface expression of 300-kDa and 120-kDa forms
was apparently SNX17 dependent. Because the 120-kDa form was
apparently observed only when the wild-type receptor was expressed,
the 300-kDa form of the wild-type receptor might be cleaved
proteolytically into 120-kDa during intracellular trafﬁcking. Goerdt et al.
[3] reported that the300-kDa form is amature formderived fromthe280-
kDa form. Further, to quantify the F2519A mutation, we generated cell
lines stably expressingwild-type FEEL-1/stabilin-1 or F2519Amutant and
selected clones that had similar expression level of FEEL-1/stabilin-1.
Then we performed quantiﬁcation of endocytosis of DiI Ac-LDL (Fig. 5C).
F2519A mutant clones were rather inactive than wild-type FEEL-1/
stabilin-1 clones as comparable to both receptors that transiently
expressed in 293A cells. Western blot analysis of total cellular FEEL-1/
stabilin-1 from these cell line suggested that F2519A mutant had low
content of 300 kDa form and apparently accumulated 280 kDa form
(Fig. 5D). Confocal microscopy of wild-type FEEL-1/stabilin-1 or F2519A
mutant clones also suggested that cell surface expression of both FEEL-1/
stabilin-1 were not signiﬁcantly different because monoclonal antibody
recognizedboth280and300 kDa formof FEEL-1/stabilin-1 (Fig. 6). It also
suggested that F2519A mutant was decreased in internalized DiI Ac-LDL
rather than cell surface DiI Ac-LDL binding.
Then the stability of cell surface FEEL-1/stabilin-1 was determined
using 293A cells that hadbeen transfectedwith siRNA for SNX17 orwith
negative control siRNA. Cotransfection of siRNAs for SNX17 with FEEL-
1/stabilin-1 reduced both the receptor activity (Fig. 7A) and the
expression levels of endogenously expressed SNX17 and transiently
expressed FEEL-1/stabilin-1, especially the 300-kDa mature form in
cells (Fig. 7B). After transfection of siRNAs for SNX17, the endocytosis
activity for Alexa-488 labeled transferrin was nearly the same as
untreated intact cells (data not shown). After biotinylation of cell
surface proteins, followed by chase incubation, the biotinylated FEEL-1/
stabilin-1was sedimentedwith streptavidin-agarose, and theamountof
biotinylated FEEL-1/stabilin-1was detected bywestern blot analysis. As
shown in Fig. 7C, while the surface-labeled FEEL-1/stabilin-1 expressed
in cellswith SNX17 siRNAwas degraded almost completelywithin 16 h,
the negative siRNA-transfected control cells still contained a consider-
able amount of biotin-labeled 300-kDa mature and 120-kDa processed
forms of FEEL-1/stabilin-1 for up to 20 h. As a result, 300-kDa and 120-
kDa forms accumulated in total FEEL-1/stabilin-1. These results suggest
that the interaction between SNX17 and the CT of FEEL-1/stabilin-1
delayed the degradation of the receptor.
Then we examined whether SNX17 binds to FEEL-1/stabilin-1 in
HUVEC. HUVEC cells were solubilized and soluble cell lysate was
immunoprecipitated with anti SNX17 antibody. As shown in Fig. 8A,
FEEL-1/stabilin-1 and SNX17 were co-immunoprecipitated with anti
SNX17 antibody in a dose dependent manner as in the case with 293A
cells that transiently expressed FEEL-1/stabilin-1. To further conﬁrm
the signiﬁcance of the interaction between FEEL-1/stabilin-1 and
SNX17, two independent siRNAs for SNX17 were transfected into
HUVECs. As shown in Fig. 8B, the cellular association of DiI Ac-LDL was
reducedwhen siRNA for FEEL-1/stabilin-1was expressed in HUVECs, as
expected [1]. The expression of siRNA for SNX17 also caused reductions
in the cellular association of DiI Ac-LDL. Notably, when siRNA for SNX17
was expressed in HUVECs, the expression levels of SNX17were reduced
and simultaneously accumulated cell surface 280-kDa form of FEEL-1/
stabilin-1 (Fig. 8C), suggesting that reducing the expression of SNX17
caused a decrease in the expression of 300-kDa form of FEEL-1/stabilin-
1 in HUVECs.
Internalization of DiI Ac-LDL and its colocalization of FEEL-1/
stabilin-1 in HUVECs upon transfection of siRNAs were shown by
confocal microscopy (Fig. 9). Transfection of siRNAs for FEEL-1
decreased its cell surface expression. Transfection of siRNA for SNX17
reduced cellular association of DiI Ac-LDL. As shown by the biotinylated
cell surface FEEL-1/stabilin-1 in HUVECs (Fig. 8C), 280 kDa form of
FEEL-1/stabilin-1 was apparently accumulated when HUVECs were
transfected with siRNA for SNX17.
Fig. 9. Confocal microscopy showing siRNA effect on HUVECs. HUVECs were seeded into wells containing sterilized coverslips and transfected siRNA using RNAiMAX. After 48 h of
transfection, cells were incubated with 1 μg/ml of DiI Ac-LDL for 3 h and then ﬁxed in 3% (w/v) paraformaldehyde for 10 min. The expression of FEEL-1/stabilin-1 was detected by
monoclonal antibody that recognizes its extracellular domain, using TSA Biotin System and streptavidin, conjugate Alexa Fluor 488.
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In this study, we demonstrated that SNX17 speciﬁcally recognized
and bound to the NPxF motif of the FEEL-1/stabilin-1 cytoplasmic
domain. Importantly,mutationof theNPxFmotif caused a complete loss
of the interaction and enhanced degradation of the receptor. It is
conceivable that FEEL-1/stabilin-1 is initially transported to the plasma
membrane as an inactive 280-kDa form in an SNX17-independent
manner. After internalization, the inactive280-kDa formbinds to SNX17
and is recycled back to the plasma membrane as a mature 300-kDa
active form. During recycling, the 300-kDa form might be cleaved
proteolytically into a 120-kDa truncated form. In the absence of SNX17,
the receptor is degraded rather rapidly in lysosomes. Taking all the data
together into consideration, our results suggest that the interactionwith
SNX17 is required for the maximum cell surface expression of FEEL-1/
stabilin-1.
It has been reported that SNX17 binds to the membrane-proximal
NPVF motif of the LDL receptor CT and thus enhances the endocytosis
and degradation of the receptor [20]. It has also shown that the
membrane-proximal NPTY motif of LRP is required for interaction with
SNX17 [19]. The loss of interaction causes decreased surface expression
and enhanced lysosomal degradation of the receptor. On the other hand,
the interaction of SNX17 with P-selectin inhibited the movement of P-
selectin into lysosomes and thereby reduced its degradation [26]. Taken
together, these results suggest that the interaction of SNX17withNPxF/
Y motif-containing receptors including FEEL-1/stabilin-1 affects intra-
cellular trafﬁcking and degradation both positively and negatively
depending on the interaction partner and thus modulates their
functions. However, we could not exclude the possibility that mutationof NPVF motif prevent the binding of other adaptor proteins to FEEL-1/
stabilin-1.
The PX domain of SNX17 is known to bind to phosphatidylinositol-3
phosphate [19,23,24]. Treatment of 293A cells that transiently express
FEEL-1/stabilin-1 with the PI-3K inhibitor wortmannin decreased
receptor activity (data not shown), suggesting that the phosphatidyli-
nositol-3-phosphate that is speciﬁcally distributed in recycling endo-
somes [22,25] is also important for FEEL-1/stabilin-1 recycling. PI-3K-
dependent intracellular trafﬁcking of scavenger receptor type IB (SR-BI)
in hepatocytes has also been reported [26,30]. Decreased hepatocyte PI-
3K activity in insulin-resistant states, such as type 2 diabetes, obesity, or
metabolic syndrome, may impair reverse cholesterol transport by
reducing the cell surface expression of SR-BI.
Although FEEL-1/stabilin-1 and FEEL-2/stabilin-2 share complex
extracellular domains containing fasciclin domains, epidermal growth
factor-like repeats, and C-type lectin-like hyaluronan-binding link
modules, the cytoplasmic domains of the receptors have no obvious
similarities [1,9]. Unlike FEEL-2/stabilin-2, the CT of FEEL-1 contains
neither the classical YXXΦ (where Φ is a bulky hydrophobic residue)
nor the NPXY consensus binding motif for AP-adaptor binding and
clathrin-mediated endocytosis [9]. Instead, FEEL-1/stabilin-1 has a
dileucine motif together with a cluster of acidic amino acids, which has
been shown to bind to the GGA that mediates the trafﬁc between the
TGN and endosome/lysosomes [10]. The presence of the NPxF motif of
the SNX17-binding site together with the GGA-binding site in FEEL-1/
stabilin-1 (but not in FEEL-2/stabilin-2) may explain the differences in
the intracellular localization of these receptors.While FEEL-1/stabilin-1
shows a largely intracellular localization, FEEL-2/stabilin-2, which
contains the plasma membrane endosomal sorting motifs NPLY and
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transported from the TGN to endosomes, where SNX17 is localized,
FEEL-1/stabilin-1 may bind to SNX17 and enter into the recycling
pathway. In the absence of SNX17-binding, it is plausible that the
lysosomal delivery of FEEL-1/stabilin-1 is enhanced through the change
of its recycling rate in the cell, and thus, cell surface receptor activity is
decreased.On theother hand, thedecreases inSNX17expressioncaused
by siRNA treatment caused a decrease in 300 kDa for of FEEL-1/stabilin-
1 expression, indicating that the interaction also affected the abundance
of the receptor in cells. It was recently reported that the interaction of
SR-BI with PDKZ1 also affected the expression and intracellular
localization of SR-BI [27]. It is plausible that the pathophysiological
functions of several receptors are regulated by their binding partners by
changing their expression and intracellular trafﬁcking levels in cells.
It is becoming evident that FEEL-1/stabilin-1 is multifunctional, and
various ligands have been reported for it. Clearance of SPARC is
mediated by FEEL-1/stabilin-1 in alternatively activated human
macrophages [13]. The matricellular protein SPARC, also known as
osteopontin, is implicated in development, differentiation, response to
injury, and tumor suppression by virtue of its regulation of extracellular
matrix production/assembly and its antiadhesive and antiproliferative
effects on different cell types [28]. FEEL-1/stabilin-1 interacting
chitinase-like protein (SI-CLP) is also shown to be a ligand for FEEL-1/
stabilin-1. Research indicates that FEEL-1/stabilin-1 was involved in
intracellular sorting of SI-CLP by binding with its extracellular domain
[29]. The extracellular levels of PL are regulated by its FEEL-1/stabilin-1-
mediated uptake and transcytosis in alternatively activated human
macrophages [15]. Furthermore, we have reported that Hsp70 is also a
ligand for FEEL-1/stabilin-1 [14]. After internalization of extracellular
Hsp70 by antigen-presenting cells (APC), the complex is thought to be
trafﬁcked into the cytoplasm or endosomal vesicles before the release,
processing, and representation of the immunogenic peptide cargo by
major histocompatibility complex (MHC) class I and II molecules at the
surface of APC [30]. Given that FEEL-1/stabilin-1 is an endocytic
receptor for these ligand proteins, it is tempting to speculate that the
receptor plays important roles in the regulation of the activities of its
ligands by regulating their degradation rates. SNX17might play roles in
facilitating FEEL-1/stabilin-1 recycling in early endosomes and regulate
the delivery of its ligands to lysosomes.
In conclusion, our ﬁndings demonstrate that SNX17 plays an
important role in the intracellular trafﬁcking and plasma membrane
localization of FEEL-1/stabilin-1 in endothelial cells. SNX17 may take
part in clearance of endocytosed ligands and thus regulate their
pathophysiological activities.
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